NDV-01 (sustained-release gemcitabine-docetaxel)
REL-NDV01-303
Phase 3 small_molecule active
Quick answer
NDV-01 (sustained-release gemcitabine-docetaxel) for Bladder (Urothelial, Transitional Cell) Cancer is a Phase 3 program (small_molecule) at RELMADA THERAPEUTICS, INC. with 2 ClinicalTrials.gov record(s).
Program details
- Company
- RELMADA THERAPEUTICS, INC.
- Indication
- Bladder (Urothelial, Transitional Cell) Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active